Detalles de la búsqueda
1.
A phase 2 trial combining afatinib with cetuximab in patients with EGFR exon 20 insertion-positive non-small cell lung cancer.
Cancer
; 130(5): 683-691, 2024 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37905752
2.
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial.
Lancet
; 401(10378): 733-746, 2023 03 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36764316
3.
Pralsetinib in patients with RET fusion-positive non-small-cell lung cancer: A plain language summary of the ARROW study.
Future Oncol
; 20(6): 297-306, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37916501
4.
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.
N Engl J Med
; 383(10): 931-943, 2020 09 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32469185
5.
Best first-line therapy for people with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status.
Cochrane Database Syst Rev
; 7: CD013382, 2023 07 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37419867
6.
Pharmacokinetically-guided dosing to improve the efficacy of brigatinib in non-small cell lung cancer patients.
Br J Clin Pharmacol
; 88(4): 1930-1934, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34545619
7.
Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy.
Cancer Metastasis Rev
; 39(3): 999-1013, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32367253
8.
Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations.
Oncologist
; 26(8): e1347-e1358, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33111480
9.
Pharmacokinetically guided dosing to improve the efficacy of brigatinib in non-small cell lung cancer patients.
Br J Clin Pharmacol
; 88(8): 3920-3921, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35350084
10.
CT-guided percutaneous hookwire localization increases the efficacy and safety of VATS for pulmonary nodules.
J Surg Oncol
; 115(7): 898-904, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-28230245
11.
First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations.
Eur J Cancer
; 196: 113458, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38039779
12.
Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer.
Lancet Reg Health Eur
; 38: 100839, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38476751
13.
Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries.
Lancet Reg Health Eur
; 38: 100838, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38476742
14.
Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nationwide registry study.
Lancet Reg Health Eur
; 27: 100592, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-36817181
15.
Amivantamab Compared with Real-World Physician's Choice after Platinum-Based Therapy from a Pan-European Chart Review of Patients with Lung Cancer and Activating EGFR Exon 20 Insertion Mutations.
Cancers (Basel)
; 15(22)2023 Nov 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38001589
16.
The additional diagnostic value of virtual bronchoscopy navigation in patients with pulmonary nodules - The NAVIGATOR study.
Lung Cancer
; 177: 37-43, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36708592
17.
Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC.
J Thorac Oncol
; 18(11): 1568-1580, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37295609
18.
A comprehensive overview of the heterogeneity of EGFR exon 20 variants in NSCLC and (pre)clinical activity to currently available treatments.
Cancer Treat Rev
; 120: 102628, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37797348
19.
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations.
Cancer Discov
; 13(3): 598-615, 2023 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36511802
20.
External validation of NTCP-models for radiation pneumonitis in lung cancer patients treated with chemoradiotherapy.
Radiother Oncol
; 186: 109735, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37327975